Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Rational design and valid… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Rational design and validation of a Tip60 histone acetyltransferase inhibitor

Artikel i vetenskaplig tidskrift
Författare Chunxia Gao
E. Bourke
M. Scobie
M. A. Famme
T. Koolmeister
T. Helleday
Leif A Eriksson
N. F. Lowndes
J. A. L. Brown
Publicerad i Scientific Reports
Volym 4
Sidor Article no: 5372
ISSN 2045-2322
Publiceringsår 2014
Publicerad vid Institutionen för kemi och molekylärbiologi
Sidor Article no: 5372
Språk en
Länkar dx.doi.org/10.1038/srep05372
Ämnesord DNA-DAMAGE RESPONSE, CANCER CELL-PROLIFERATION, DOUBLE-STRAND BREAKS, ANDROGEN RECEPTOR, DEACETYLASE INHIBITORS, FORCE-FIELD, ACETYLATION, REPAIR, ATM, ACTIVATION, Multidisciplinary Sciences
Ämneskategorier Mikrobiologi

Sammanfattning

Histone acetylation is required for many aspects of gene regulation, genome maintenance and metabolism and dysfunctional acetylation is implicated in numerous diseases, including cancer. Acetylation is regulated by histone acetyltransferases (HATs) and histone deacetylases and currently, few general HAT inhibitors have been described. We identified the HAT Tip60 as an excellent candidate for targeted drug development, as Tip60 is a key mediator of the DNA damage response and transcriptional co-activator. Our modeling of Tip60 indicated that the active binding pocket possesses opposite charges at each end, with the positive charges attributed to two specific side chains. We used structure based drug design to develop a novel Tip60 inhibitor, TH1834, to fit this specific pocket. We demonstrate that TH1834 significantly inhibits Tip60 activity in vitro and treating cells with TH1834 results in apoptosis and increased unrepaired DNA damage (following ionizing radiation treatment) in breast cancer but not control cell lines. Furthermore, TH1834 did not affect the activity of related HAT MOF, as indicated by H4K16Ac, demonstrating specificity. The modeling and validation of the small molecule inhibitor TH1834 represents a first step towards developing additional specific, targeted inhibitors of Tip60 that may lead to further improvements in the treatment of breast cancer.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?